Aurora Cannabis Inc.

NASDAQ:ACB

Drug Manufacturers - Specialty & Generic

Healthcare
$4.40 +0.51%

+$0.02 today

Market cap
$289.28M
Beta
1.34
P/E (TTM)
-3.2
EPS (TTM)
-$1.31
52W Low $2.73High $6.67

Volume 0.92M

Average 1.00M

ACB Depreciation & Amortization

Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.

Aurora Cannabis Inc.NASDAQ: ACB

Depreciation & Amortization · Q4 FY2026 · quarter ended Mar 2026

Depreciation & amortization turns negative

Q4 FY2026 depreciation & amortization was -CA$4.62M, compared with CA$5.95M a year earlier. Trailing-twelve-month depreciation & amortization was CA$13.44M. Over 3 fiscal years it compounded at -35.3% a year.

Context

  • Depreciation & amortization amounted to 4.4% of revenue in FY2026, down 2.1 pp from a year earlier.
  • Depreciation & amortization increased in 0 of the last 3 fiscal years.
  • FY2026 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly depreciation & amortization holds near -CA$4.62M or moves back toward the trailing-twelve-month quarterly average of CA$3.36M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-CA$4.62M-172.2% QoQ
Last fiscal yearMar 2026
CA$14.23M-36.9% YoY
LTMMar 2026
CA$13.44M-40.4% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-177.6%——
1 year-36.9%——
3-year CAGR-35.3%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

CAD · from the income statement

Latest · FY2026
14.23M CAD
Year-over-year change
-36.9%
4-year CAGR
-37.6%

Depreciation & Amortization vs competitors

How ACB compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -40.4% is the lowest of 10, against a peer median of -2.9%.
  • Depreciation & amortization amounts to 4.3% of revenue for ACB, versus a peer median of 6.8%.
ACB Competitors
Depreciation & Amortization for ACB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CGCCanopy Growth CorporationLTM Mar 2026CA$39.79M CAD-7.7%-14.0%12.7%
HITIHigh Tide Inc.LTM Apr 2026CA$20.62M CAD-9.4%-6.9%3.1%
OGIOrganigram Global Inc.LTM Mar 2026CA$19.76M CAD+37.8%—7.2%
ACBAurora Cannabis Inc.LTM Mar 2026CA$13.44M CAD-40.4%-35.3%4.3%
LFCRLifecore Biomedical, Inc.LTM Mar 2026$9.77M USD—-23.7%7.2%
LFMDLifeMD, Inc.LTM Mar 2026$9.76M USD-2.9%+88.7%4.4%
TKNOAlpha Teknova, Inc.LTM Mar 2026$6.34M USD-2.8%+26.1%15.2%
EDITEditas Medicine, Inc.LTM Mar 2026$3.84M USD-39.2%-5.9%9.9%
IRWDIronwood Pharmaceuticals, Inc.LTM Mar 2026$1.85M USD-6.7%+9.9%0.5%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$528K USD+7.3%-17.1%6.3%
BIOABioAge Labs, Inc.LTM Mar 2026$239K USD+39.8%+18.2%2.3%
Peer median (excluding ACB) —-2.9%-5.9%6.8%

Competitors are the stored peer set for ACB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CAD
Metric
FY2022
Jun 2022
FY2023
Mar 2023
FY2024
Mar 2024
FY2025
Mar 2025
FY2026
Mar 2026
Revenue221.34M223.8M270.28M343.29M321.42M
Cost of Revenue200.11M209.02M138.82M155.69M304.67M
Gross Profit21.23M14.78M131.46M187.61M16.75M
Gross Margin9.6%6.6%48.6%54.6%5.2%
Research & Development10.39M5.77M3.57M3.68M6.01M
Selling, General & Admin188.99M170.48M156.88M166.47M173.95M
Operating Expenses252.67M221.98M177.91M182.66M179.96M
Depreciation & Amortization93.66M52.59M33.07M22.55M14.23M
EBITDA(1.55B)(135M)(12.34M)51.35M(148.99M)
EBITDA Margin-702.4%-60.3%-4.6%15.0%-46.4%
Operating Income(231.45M)(207.19M)(46.45M)4.95M(163.21M)
Operating Margin-104.6%-92.6%-17.2%1.4%-50.8%
Interest Income4.51M19M12.81M11.51M5.86M
Interest Expense71.81M39.46M14.19M8.42M1.81M
Other Income / Expenses(1.49B)(576.51M)(13.15M)15.43M106.54M
Income Before Tax(1.72B)(783.7M)(59.6M)20.38M(56.67M)
Pre-Tax Margin-777.1%-350.2%-22.1%5.9%-17.6%
Income Tax Expense(2.14M)16.55M(554K)4.62M2.1M
Net Income(1.72B)(816.63M)(69.33M)1.59M(122.07M)
Net Margin-776.0%-364.9%-25.6%0.5%-38.0%
EPS (Basic)(79.92)(8.17)(1.28)0.03(2.15)
EPS (Diluted)(79.92)(8.17)(1.28)0.03(2.15)
Weighted Avg Shares21.49M32.27M51.26M54.88M56.71M
Weighted Avg Shares (Diluted)21.49M32.27M51.26M55.75M56.71M

Aurora Cannabis Inc.

NASDAQ:ACB

Intrinsic Alpha fair value

Locked

Current Price

$4.40

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.